NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its first quarter revenues rose 23 percent, driven in part by sales of its Nanosphere Verigene molecular products, which rose 59 percent over the prior-year quarter to $10.5 million.

For the three months ended March 31, the firm reported revenues of $77.8million, up from $63.0 million a year ago, and beating the consensus Wall Street estimate of $74.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.